Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%

Healthcare

Page 102
  1. Nov 13, 2025 · 18:32 · MBIO

    Mindbio talks initial MB22001 phase 2B trial results

    Mindbio talks initial MB22001 phase 2B trial results

    01
  2. Nov 13, 2025 · 17:43 · MDNA

    Medicenna's fiscal Q2 2026 R&D expenses at $4.1M

    Medicenna's fiscal Q2 2026 R&D expenses at $4.1M

    02
  3. Nov 13, 2025 · 17:40 · CRDL

    Cardiol gains U.S. patent for heart drugs to 2040

    Cardiol gains U.S. patent for heart drugs to 2040

    03
  4. Nov 13, 2025 · 17:30 · MPH

    Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025

    Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025

    04
  5. Nov 13, 2025 · 17:21 · APLI

    Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

    Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

    05
  6. Nov 13, 2025 · 17:01 · WELL

    Well Health's OceanMD wins e-referral contract

    Well Health's OceanMD wins e-referral contract

    06
  7. Nov 13, 2025 · 17:00 · EPRX

    Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

    Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

    07
  8. Nov 13, 2025 · 17:00 · APS

    Aptose Reports Third Quarter 2025 Results

    Aptose Reports Third Quarter 2025 Results

    08
  9. Nov 13, 2025 · 16:37 · SVA

    Sernova closes $874,600 first tranche of placement

    Sernova closes $874,600 first tranche of placement

    09
  10. Nov 13, 2025 · 16:08 · FRX

    Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

    Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

    10
  11. Nov 13, 2025 · 16:05 · PRN

    Profound Medical Reports Strong Third Quarter 2025 Financial Results

    Profound Medical Reports Strong Third Quarter 2025 Financial Results

    11
  12. Nov 13, 2025 · 16:01 · VITA

    Vitalist Reports Second Quarter 2026 Financial Results

    Vitalist Reports Second Quarter 2026 Financial Results

    12
  13. Nov 13, 2025 · 16:01 · FRX

    Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

    Fennec Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

    13
  14. Nov 13, 2025 · 10:57 · HEM

    Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway

    Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway

    14
← Newer Older →